Bifalgorithm post · ASCO 2026: Studies Aim to Expand Treatment Options for Lung Cancer · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib

Safety Profile

Safety Profile (ASCO 2026: Studies Aim to Expand Treatment Options for Lung Cancer · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib) — "Treatment-emergent…

Ideas in this flowchart

  • Treatment-emergent adverse events (TEAEs) reported during the trial
  • Any-grade TEAEs were consistent with prior reports
  • EGFR inhibition-related events: paronychia (78%), rash (65%), diarrhea (35%), stomatitis (35%), and pruritus (31%)
  • MET inhibition-related events: hypoalbuminemia (61%) and peripheral edema (41%)
  • TEAEs of grade 3 or higher
  • EGFR inhibition-related grade 3 or higher events: paronychia (8%) and rash (14%)
  • MET inhibition-related grade 3 or higher events: hypoalbuminemia (6%) and peripheral edema (2%)
  • Other grade 3 or higher TEAEs: infusion-related reactions (6%), ALT elevation (4%), AST elevation (2%), and nausea (2%)
  • COVID-19 developed in 20 patients (41%); one patient had grade 3 or higher symptoms
Bifalgorithm
Sign up
Feed/

Safety Profile

No cover

Channel

ASCO 2026: Studies Aim to Expand Treatment Options for Lung Cancer

1 page

U
USR292600b83e2a
Ebook2w

"Treatment-emergent adverse events (TEAEs) were consistent with prior reports and included any-grade EGFR inhibition-related paronychia (78%), rash (65%), diarrhea and stomatitis (each 35%), and pruritus (31%); and MET inhibition-related hypoalbuminemia (61%) and peripheral edema (41%).\n\nTEAEs of grade 3 or higher included EGFR inhibition-related paronychia (8%) and rash (14%), and MET inhibition-related hypoalbuminemia (6%) and peripheral edema (2%). Other TEAEs of grade 3 or higher included infusion-related reactions in 6% of patients, ALT elevation in 4%, AST elevation in 2%, and nausea in 2%. Twenty patients (41%) developed COVID-19 during the trial, 1 of whom had symptoms of grade 3 or higher."

Flowchart preview
👍
0
0 comments0 shares

Sign in to view and post comments.